Your session is about to expire
← Back to Search
PF-06730512 for Focal Segmental Glomerulosclerosis (PODO Trial)
PODO Trial Summary
This trial is testing a new drug to see if it's effective and safe for people with FSGS.
- Focal Segmental Glomerulosclerosis
PODO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPODO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PODO Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment for this investigation still open?
"According to the clinicaltrials.gov records, this study is no longer actively seeking participants as of November 7th 2022. Although it cannot accept applicants at present, there are 15 other trials which currently require patient enrolment."
Does PF-06730512 present any health hazards to trial participants?
"The safety of PF-06730512 has been judged to be a 2 on the 1-3 scale, since this is only in its second trial phase; there is some evidence indicating an acceptable level of security but none that confirms efficacy."
Which settings are currently providing access to this trial?
"Patients can be accepted into this research trial at Stanford University-Nephrology Division, CIUSSS de l'Est-de-l'Ile-de-Montreal - installation Hopital Maisonneuve-Rosemont, and UNC Clinical and Translational Research Center; additionally there are 63 other sites that have been approved."
Share this study with friends
Copy Link
Messenger